Chemotherapy News and Research

Latest Chemotherapy News and Research

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.

25 Feb 2013

Researchers identify new pseudogene that regulates tumour-suppressing PTEN

Researchers at Karolinska Institutet in Sweden have identified a new so-called pseudogene that regulates the tumour-suppressing PTEN gene. They hope that this pseudogene will be able to control PTEN to reverse the tumour process, make the cancer tumour more sensitive to chemotherapy and to prevent the development of resistance.

25 Feb 2013

New, effective and less toxic therapeutic option for patients with HER2-positive breast cancer

Patients with HER2-positive breast cancer, a particularly aggressive form of breast cancer, now have a new, effective and less toxic therapeutic option.

24 Feb 2013

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

23 Feb 2013

New research offers clues for chemotherapy-induced cognitive impairment

It's not unusual for cancer patients being treated with chemotherapy to complain about not being able to think clearly, connect thoughts or concentrate on daily tasks. The complaint - often referred to as chemo-brain - is common. The scientific cause, however, has been difficult to pinpoint.

22 Feb 2013

Weekend reading: Why a trip to the ER costs more than a college semester; Searching for the 'stomach share;' Lessons for the U.S. from Rwanda

Routine Care, Unforgettable Bills .... Sean was allowed to see the doctor only after he advanced MD Anderson $7,500 from his credit card. ... The total cost, in advance, for Sean to get his treatment plan and initial doses of chemotherapy was $83,900.

21 Feb 2013

Article provides examples of how epigenetic drug treatments could be beneficial in treating cancers

A review article by researchers at Boston University School of Medicine (BUSM) proposes a new epigenetic hypothesis linked to tumor production and novel ideas about what causes progenitor cells to develop into cancer cells. Published in the February 2013 issue of Epigenomics, the article provides examples of how epigenetic drug treatments could be beneficial in treating cancers while also decreasing the likelihood of cancer relapse.

21 Feb 2013

‘Liver first’ approach first choice for metastatic rectal cancer

Using the “liver first” approach to treat locally advanced rectal cancer and synchronous liver metastases allows nearly three-quarters of patients to receive optimal neoadjuvant therapy and resection for both their primary tumor and metastases, researchers report.

20 Feb 2013

Study investigates whether music therapy reduces stress in cancer patients

A Saint Louis University Cancer Center pilot study is investigating whether music affects the health of cancer patients by soothing them and making them less anxious.

19 Feb 2013

Clonal evolution explains unpredictable leukemia disease course

Scientists have revealed the complicated clonal evolution of chronic lymphocytic leukemia, giving insight into the variation in disease course and its response to treatment.

19 Feb 2013

Shorter version of abPG-SGA can potentially improve outcomes for cancer patients

Considering the many things a cancer patient has to think about, it's easy to understand why maintaining proper nutrition may not be top of mind. This can be true, too, at busy outpatient settings where it's often difficult to find the time and resources to test cancer patients for malnutrition.

18 Feb 2013

Research involves new, safer ways to deliver biomedical agents against tumors

Jeremy L. Steinbacher, PhD, is among a new generation of scientists trying to improve their aim and approach to killing cancer cells. The Canisius College professor of chemistry/biochemistry is working to develop biomedical agents that more accurately target and attack tumors.

16 Feb 2013

IKBKE gene plays a key role in tobacco-induced lung cancer

Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.

16 Feb 2013

Tumor texture analysis has prognostic potential

Tumor texture analysis, determined by computed tomography, holds promise as a prognostic biomarker in patients with esophageal cancer, research indicates.

15 Feb 2013

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.

15 Feb 2013

Patient-specific cancer cell lines designed to predict chemotherapy sensitivity

In laboratory studies, scientists at the Johns Hopkins Kimmel Cancer Center have developed a way to personalize chemotherapy drug selection for cancer patients by using cell lines created from their own tumors.

15 Feb 2013

Researchers show how gene mutations shift and evolve over time in chronic lymphocytic leukemia

Tumors are not factories for the mass production of identical cancer cells, but are, in reality, patchworks of cells with different patterns of gene mutations. In a new study, researchers at Dana-Farber Cancer Institute and the Broad Institute show, more fully than ever before, how these mutations shift and evolve over time in chronic lymphocytic leukemia (CLL) - providing a strobe-like look at the genetic past, present, and future of CLL tumors.

15 Feb 2013

University of Granada’s melatonin gel effective against mucositis

Mucositis is one of the most frequent side effects of chemotherapy and radiotherapy in cancer patients and currently cannot be treated. Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction.

15 Feb 2013

DNA repair mechanisms tied to reproductive aging

Age-related decline in the efficacy of DNA repair may underlie reproductive aging, say researchers.

14 Feb 2013

Regeneron fourth quarter total revenues increase to $415 million

Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.

14 Feb 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Researchers identify new pseudogene that regulates tumour-suppressing PTEN

New, effective and less toxic therapeutic option for patients with HER2-positive breast cancer

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

New research offers clues for chemotherapy-induced cognitive impairment

Weekend reading: Why a trip to the ER costs more than a college semester; Searching for the 'stomach share;' Lessons for the U.S. from Rwanda

Article provides examples of how epigenetic drug treatments could be beneficial in treating cancers

‘Liver first’ approach first choice for metastatic rectal cancer

Study investigates whether music therapy reduces stress in cancer patients

Clonal evolution explains unpredictable leukemia disease course

Shorter version of abPG-SGA can potentially improve outcomes for cancer patients

Research involves new, safer ways to deliver biomedical agents against tumors

IKBKE gene plays a key role in tobacco-induced lung cancer

Tumor texture analysis has prognostic potential

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

Patient-specific cancer cell lines designed to predict chemotherapy sensitivity

Researchers show how gene mutations shift and evolve over time in chronic lymphocytic leukemia

University of Granada’s melatonin gel effective against mucositis

DNA repair mechanisms tied to reproductive aging

Regeneron fourth quarter total revenues increase to $415 million

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in